Ariad submits EU MAA for ponatinib and prepares to storm Europe
This article was originally published in Scrip
Executive Summary
Ariad Pharmaceuticals has submitted its marketing authorisation application to the European Medicines Agency for ponatinib for resistant or intolerant chronic myeloid leukaemia and Philadelphia-chromosome positive acute lymphoblastic leukaemia. Tim Clackson, the firm's CSO and president of R&D, explained how Ariad will makes it name in the European oncology market and why partnering is not the way to do it.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.